Finance Watch: Lexeo Launches 20th US Biopharma IPO In 2023
Blue Owl Buys $1bn In Assets Managed By Cowen
Public Company Edition: Lexeo raised $100m to advance its genetic medicines. Also, Blue Owl Capital acquired funds managed by Cowen Healthcare Investments, gaining about $1bn in life science assets, BMS priced $4.5bn in notes to fund its Mirati purchase and Viridian raised $185m in a private placement.
